查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529641

偏頭痛藥物市場規模、佔有率、趨勢分析報告：按治療層級、途徑、治療、年齡層、按性別、地區、細分市場預測分類的可用性，2024-2030 年

Migraine Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (Ditans, NSAIDs), By Route Of Administration (Oral, Injectable), By Treatment, By Age Group, By Availability, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 159 Pages | 商品交期: 2-10個工作天內

價格

偏頭痛藥物市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球偏頭痛藥物市場規模預計將達到133.4億美元，預測期內複合年成長率為11.9%。

該市場主要受到疾病盛行率上升、新治療方法開發、生活方式改變和荷爾蒙藥物等因素的推動。

偏頭痛是一種使人衰弱的神經系統疾病，其特徵是反覆發作持續三天或更長時間的劇烈頭痛。偏頭痛隨著運動而加劇，並可能妨礙患者進行正常的日常活動。大約三分之一的攻擊會影響頭部、臉部和頸部的兩側。

過去五年，全球偏頭痛藥物市場相對停滯，主要由非專利藥曲坦類藥物和其他仿單標示外藥物主導。目前大多數處方藥物，無論是用於急性治療或預防性治療，療效都很差且有不良副作用。

安進/諾華的 CGRP mAb Aimovig 和 Teva Pharma 的 Ajovy 的推出是改變偏頭痛預防治療模式的第一步。對於禮來(Eli Lilly)、Alder BioPharma 和Biohaven Pharma 等可能在2019 年進入市場的藥品製造商來說，基於CGRP 的療法都將具有相似的功效和安全性，使它們更加實惠似乎是差異化的關鍵。

偏頭痛藥物市場報告亮點

  • 由於疾病盛行率上升、新藥上市以及研發活動增加，德國在歐洲市場處於領先地位。
  • 急性偏頭痛治療市場得到了新型藥物類別的快速採用的支持，例如 CGRP 受體拮抗劑和地坦藥物，目前正在多個 II/III 期試驗中積極研究這些藥物。
  • Biohaven 的 rimegepant 預計將面臨艾爾建 (Allergan) 的 ubrogepant 的競爭，後者在 III 期試驗中顯示出比 rimegepant 更優越的療效。
  • 禮來公司的 III 期 5-HT1F促效劑lasmiditan 有望成為曲坦類藥物無效患者的新型一線非曲坦類急性治療藥物。
  • 大約 20% 尋求偏頭痛預防性治療的患者對現有的學名藥沒有反應。針對預防性治療領域未滿足的高需求的幾種生技藥品和小分子藥物正在積極開發中。
  • 早期開發階段的新標靶藥物包括AOBiome Therapeutics的AOB-203（抗菌劑）、Winston Pharma的Dolorac（組胺H1受體拮抗劑）、NeuroAxons的NXN-188（NOS抑制劑和曲普坦組合） 、Biohaven的BHV-3500（gepant） ， ETC。這些新型藥物正在針對陣發性和慢性偏頭痛的多項 I/II 期試驗中進行評估。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章偏頭痛藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 偏頭痛藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
    • 管道分析
    • 目標人口分析

第4章偏頭痛藥物市場：依治療方法估算與趨勢分析

  • 全球偏頭痛藥物市場：治療儀表板
  • 全球偏頭痛藥物市場：治療變異分析
  • 按治療分類的收益
  • 急性
  • 預防

第5章偏頭痛藥物市場：依治療層級估計與趨勢分析

  • 全球偏頭痛藥物市場：治療層級儀表板
  • 全球偏頭痛藥物市場：治療層級變異分析
  • 按治療層級的收益
  • CGRP單株抗體
  • CGRP小分子拮抗劑
  • 乙醯膽鹼抑制劑/神經毒素
  • 曲普坦
  • 德坦斯
  • 麥角生物鹼
  • NSAIDs
  • 其他

第6章偏頭痛藥物市場：依給藥途徑估計與趨勢分析

  • 全球偏頭痛藥物市場：途徑途徑儀表板
  • 全球偏頭痛藥物市場：途徑變化分析
  • 途徑的收益
  • 口服
  • 注射
  • 其他

第7章偏頭痛藥物市場：依年齡層別估計及趨勢分析

  • 全球偏頭痛藥物市場：年齡族群板
  • 全球偏頭痛藥物市場：年齡層波動分析
  • 按年齡層別分類的收益
  • 兒科的
  • 成人
  • 老年人

第8章偏頭痛藥物市場：可獲得性別性別估計及趨勢分析

  • 全球偏頭痛藥物市場：可用性儀表板
  • 全球偏頭痛藥物市場：可用性變化分析
  • 可用性 性別收益
  • 處方藥
  • 非處方藥 (OTC)

第9章偏頭痛藥物市場：治療、治療層級、給藥途徑、年齡層、可用性性別區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第10章競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 主要客戶
    • 2023年主要企業市場佔有率分析
    • AbbVie Inc.
    • Amgen Inc.
    • Teva Pharmaceutical Industries Ltd.
    • GSK plc
    • Eli Lilly and Company
    • Pfizer Inc.
    • Bausch Health Companies Inc.
    • Gensco Pharma
    • Impel Pharmaceuticals Inc.
    • Currax Pharmaceuticals LLC.
    • Lundbeck
Product Code: GVR-2-68038-559-5

Migraine Drugs Market Growth & Trends:

The global migraine drugs market size is expected to be valued at USD 13.34 billion by 2030, as per a new report by Grand View Research, Inc., exhibiting an 11.9% CAGR during the forecast period. The market is largely driven by factors such as a rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.

Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.

Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.

Launch of Amgen/ Novartis' CGRP mAb Aimovig and Teva Pharma's Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.

Migraine Drugs Market Report Highlights:

  • Germany leads the European market, driven by rising disease prevalence, novel drug launches, and an increase in R&D activities
  • The acute migraine treatment market will be supported by the rapid uptake of novel drug classes such as CGRP receptor antagonists and ditans currently under active investigation in multiple Phase II/III trials
  • Biohaven's rimegepant is expected to face competition from Allergan's ubrogepant, which has shown superior efficacy in Phase III trials compared to rimegepant
  • Eli Lilly's Phase III 5-HT1F receptor agonist Lasmiditan is expected to be a novel first-line non triptan acute treatment option for patients in whom triptans are contradicted
  • Approximately 20% of patients seeking preventive treatment for migraine do not respond to available generic medications. Several biologics and small molecules drugs are undergoing active development to target high unmet needs in the preventive treatment segment
  • Drugs with novel targets in early-phase development include AOBiome Therapeutics' AOB-203 (antibacterial), Winston Pharma's Dolorac (histamine H1 receptor antagonists), NeuroAxons' NXN-188 (a combination of NOS inhibitor and a triptan), and Biohaven's BHV-3500 (gepant). These novel agents are under evaluation for both episodic and chronic migraine in multiple Phase I/II trials.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Therapeutic Class
    • 1.2.3. Route of Administration
    • 1.2.4. Age Group
    • 1.2.5. Availability
    • 1.2.6. Regional scope
    • 1.2.7. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. Therapeutic Class Outlook
    • 2.2.3. Route of Administration Outlook
    • 2.2.4. Age Group Outlook
    • 2.2.5. Availability Outlook
    • 2.2.6. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Migraine Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing prevalence of migraines
      • 3.2.1.2. Advancements in drug development
      • 3.2.1.3. Growing awareness and diagnosis
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High cost of development
      • 3.2.2.2. Regulatory challenges for new drug approvals
  • 3.3. Migraine Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Target population analysis

Chapter 4. Migraine Drugs Market: Treatment Estimates & Trend Analysis

  • 4.1. Global Migraine Drugs Market: Treatment Dashboard
  • 4.2. Global Migraine Drugs Market: Treatment Movement Analysis
  • 4.3. Global Migraine Drugs Market by Treatment, Revenue
  • 4.4. Acute
    • 4.4.1. Acute market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Preventive
    • 4.5.1. Preventive market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Migraine Drugs Market: Therapeutic Class Estimates & Trend Analysis

  • 5.1. Global Migraine Drugs Market: Therapeutic Class Dashboard
  • 5.2. Global Migraine Drugs Market: Therapeutic Class Movement Analysis
  • 5.3. Global Migraine Drugs Market Estimates and Forecasts, By Therapeutic Class, Revenue (USD Million)
  • 5.4. CGRP Monoclonal Antibodies
    • 5.4.1. CGRP monoclonal antibodies market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. CGRP Small Molecule Antagonists
    • 5.5.1. CGRP small molecule antagonists market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Acetylcholine Inhibitors/ neurotoxins
    • 5.6.1. Acetylcholine inhibitors/ neurotoxins market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. Triptans
    • 5.7.1. Triptans market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.8. Ditans
    • 5.8.1. Ditans market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.9. Ergot alkaloids
    • 5.9.1. Ergot alkaloids market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.10. NSAIDs
    • 5.10.1. NSAIDs market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.11. Others
    • 5.11.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Migraine Drugs Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global Migraine Drugs Market: Route of Administration Dashboard
  • 6.2. Global Migraine Drugs Market: Route of Administration Movement Analysis
  • 6.3. Global Migraine Drugs Market Estimates and Forecasts, by Route of Administration, Revenue (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Injectable
    • 6.5.1. Injectable market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Migraine Drugs Market: Age Group Estimates & Trend Analysis

  • 7.1. Global Migraine Drugs Market: Age Group Dashboard
  • 7.2. Global Migraine Drugs Market: Age Group Movement Analysis
  • 7.3. Global Migraine Drugs Market Estimates and Forecasts by Age Group, Revenue (USD Million)
  • 7.4. Pediatric
    • 7.4.1. Pediatric market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5. Adult
    • 7.5.1. Adult market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6. Geriatric
    • 7.6.1. Geriatric market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Migraine Drugs Market: Availability Estimates & Trend Analysis

  • 8.1. Global Migraine Drugs Market: Availability Dashboard
  • 8.2. Global Migraine Drugs Market: Availability Movement Analysis
  • 8.3. Global Migraine Drugs Market Estimates and Forecasts, by Availability, Revenue (USD Million)
  • 8.4. Prescription Drugs
    • 8.4.1. Prescription Drugs market estimates and forecasts 2018 - 2030 (USD Million)
  • 8.5. Over-the-Counter (OTC) Drugs
    • 8.5.1. Over-the-Counter (OTC) Drugs market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 9. Migraine Drugs Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, Route of Administration, Age Groupd and Availability

  • 9.1. Regional Dashboard
  • 9.2. Market Size, & Forecasts Trend Analysis, 2018 - 2030
  • 9.3. North America
    • 9.3.1. U.S.
      • 9.3.1.1. Key country dynamics
      • 9.3.1.2. Regulatory framework/ reimbursement structure
      • 9.3.1.3. Competitive scenario
      • 9.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.3.2. Canada
      • 9.3.2.1. Key country dynamics
      • 9.3.2.2. Regulatory framework/ reimbursement structure
      • 9.3.2.3. Competitive scenario
      • 9.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.3.3. Mexico
      • 9.3.3.1. Key country dynamics
      • 9.3.3.2. Regulatory framework/ reimbursement structure
      • 9.3.3.3. Competitive scenario
      • 9.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4. Europe
    • 9.4.1. UK
      • 9.4.1.1. Key country dynamics
      • 9.4.1.2. Regulatory framework/ reimbursement structure
      • 9.4.1.3. Competitive scenario
      • 9.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.2. Germany
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Regulatory framework/ reimbursement structure
      • 9.4.2.3. Competitive scenario
      • 9.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.3. France
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Regulatory framework/ reimbursement structure
      • 9.4.3.3. Competitive scenario
      • 9.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.4. Italy
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Regulatory framework/ reimbursement structure
      • 9.4.4.3. Competitive scenario
      • 9.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.5. Spain
      • 9.4.5.1. Key country dynamics
      • 9.4.5.2. Regulatory framework/ reimbursement structure
      • 9.4.5.3. Competitive scenario
      • 9.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.6. Denmark
      • 9.4.6.1. Key country dynamics
      • 9.4.6.2. Regulatory framework/ reimbursement structure
      • 9.4.6.3. Competitive scenario
      • 9.4.6.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.7. Norway
      • 9.4.7.1. Key country dynamics
      • 9.4.7.2. Regulatory framework/ reimbursement structure
      • 9.4.7.3. Competitive scenario
      • 9.4.7.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.4.8. Sweden
      • 9.4.8.1. Key country dynamics
      • 9.4.8.2. Regulatory framework/ reimbursement structure
      • 9.4.8.3. Competitive scenario
      • 9.4.8.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Japan
      • 9.5.1.1. Key country dynamics
      • 9.5.1.2. Regulatory framework/ reimbursement structure
      • 9.5.1.3. Competitive scenario
      • 9.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.2. China
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework/ reimbursement structure
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.3. India
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework/ reimbursement structure
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.4. Australia
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Regulatory framework/ reimbursement structure
      • 9.5.4.3. Competitive scenario
      • 9.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.5. South Korea
      • 9.5.5.1. Key country dynamics
      • 9.5.5.2. Regulatory framework/ reimbursement structure
      • 9.5.5.3. Competitive scenario
      • 9.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.5.6. Thailand
      • 9.5.6.1. Key country dynamics
      • 9.5.6.2. Regulatory framework/ reimbursement structure
      • 9.5.6.3. Competitive scenario
      • 9.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Brazil
      • 9.6.1.1. Key country dynamics
      • 9.6.1.2. Regulatory framework/ reimbursement structure
      • 9.6.1.3. Competitive scenario
      • 9.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.6.2. Argentina
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework/ reimbursement structure
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.7. MEA
    • 9.7.1. South Africa
      • 9.7.1.1. Key country dynamics
      • 9.7.1.2. Regulatory framework/ reimbursement structure
      • 9.7.1.3. Competitive scenario
      • 9.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.2. Saudi Arabia
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Regulatory framework/ reimbursement structure
      • 9.7.2.3. Competitive scenario
      • 9.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.3. UAE
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Regulatory framework/ reimbursement structure
      • 9.7.3.3. Competitive scenario
      • 9.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 9.7.4. Kuwait
      • 9.7.4.1. Key country dynamics
      • 9.7.4.2. Regulatory framework/ reimbursement structure
      • 9.7.4.3. Competitive scenario
      • 9.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. List of key distributors and channel partners
    • 10.3.2. Key customers
    • 10.3.3. Key company market share analysis, 2023
    • 10.3.4. AbbVie Inc.
      • 10.3.4.1. Company overview
      • 10.3.4.2. Financial performance
      • 10.3.4.3. Product benchmarking
      • 10.3.4.4. Strategic initiatives
    • 10.3.5. Amgen Inc.
      • 10.3.5.1. Company overview
      • 10.3.5.2. Financial performance
      • 10.3.5.3. Product benchmarking
      • 10.3.5.4. Strategic initiatives
    • 10.3.6. Teva Pharmaceutical Industries Ltd.
      • 10.3.6.1. Company overview
      • 10.3.6.2. Financial performance
      • 10.3.6.3. Product benchmarking
      • 10.3.6.4. Strategic initiatives
    • 10.3.7. GSK plc
      • 10.3.7.1. Company overview
      • 10.3.7.2. Financial performance
      • 10.3.7.3. Product benchmarking
      • 10.3.7.4. Strategic initiatives
    • 10.3.8. Eli Lilly and Company
      • 10.3.8.1. Company overview
      • 10.3.8.2. Financial performance
      • 10.3.8.3. Product benchmarking
      • 10.3.8.4. Strategic initiatives
    • 10.3.9. Pfizer Inc.
      • 10.3.9.1. Company overview
      • 10.3.9.2. Financial performance
      • 10.3.9.3. Product benchmarking
      • 10.3.9.4. Strategic initiatives
    • 10.3.10. Bausch Health Companies Inc.
      • 10.3.10.1. Company overview
      • 10.3.10.2. Financial performance
      • 10.3.10.3. Product benchmarking
      • 10.3.10.4. Strategic initiatives
    • 10.3.11. Gensco Pharma
      • 10.3.11.1. Company overview
      • 10.3.11.2. Financial performance
      • 10.3.11.3. Product benchmarking
      • 10.3.11.4. Strategic initiatives
    • 10.3.12. Impel Pharmaceuticals Inc.
      • 10.3.12.1. Company overview
      • 10.3.12.2. Financial performance
      • 10.3.12.3. Product benchmarking
      • 10.3.12.4. Strategic initiatives
    • 10.3.13. Currax Pharmaceuticals LLC.
      • 10.3.13.1. Company overview
      • 10.3.13.2. Financial performance
      • 10.3.13.3. Product benchmarking
      • 10.3.13.4. Strategic initiatives
    • 10.3.14. Lundbeck
      • 10.3.14.1. Company overview
      • 10.3.14.2. Financial performance
      • 10.3.14.3. Product benchmarking
      • 10.3.14.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America migraine drugs market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 4 North America migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 5 North America migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 6 North America migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 7 North America migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 8 U.S. migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 9 U.S. migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 10 U.S. migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 U.S. migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 12 U.S. migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 13 Canada migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Canada migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 15 Canada migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16 Canada migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 17 Canada migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 18 Mexico migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 Mexico migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 20 Mexico migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 21 Mexico migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 22 Mexico migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 23 Europe migraine drugs market, by region, 2018 - 2030 (USD Million)
  • Table 24 Europe migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Europe migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 26 Europe migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Europe migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 28 Europe migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 29 Germany migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 30 Germany migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 31 Germany migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 32 Germany migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 33 Germany migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 34 UK migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 35 UK migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 36 UK migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 UK migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 38 UK migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 39 France migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 40 France migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 41 France migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 42 France migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 43 France migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 44 Italy migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 45 Italy migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 46 Italy migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Italy migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 48 Italy migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 49 Spain migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 50 Spain migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 51 Spain migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Spain migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 53 Spain migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 54 Denmark migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 55 Denmark migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 56 Denmark migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57 Denmark migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 58 Denmark migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 59 Sweden migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 Sweden migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 61 Sweden migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 62 Sweden migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 63 Sweden migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 64 Norway migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 65 Norway migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 66 Norway migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 67 Norway migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 68 Norway migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 69 Asia Pacific migraine drugs market, by region, 2018 - 2030 (USD Million)
  • Table 70 Asia Pacific migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 71 Asia Pacific migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 72 Aisa Pacific migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 Asia Pacific migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 74 Aisa Pacific migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 75 China migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 76 China migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 77 China migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78 China migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 79 China migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 80 Japan migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 81 Japan migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 82 Japan migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 83 Japan migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 84 Japan migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 85 India migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 86 India migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 87 India migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 88 India migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 89 India migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 90 South Korea migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 91 South Korea migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 92 South Korea migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 93 South Korea migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 94 South Korea migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 95 Australia migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 96 Australia migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 97 Australia migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 98 Australia migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 99 Australia migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 100 Thailand migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 101 Thailand migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 102 Thailand migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 103 Thailand migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 104 Thailand migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 105 Latin America migraine drugs market, by region, 2018 - 2030 (USD Million)
  • Table 106 Latin America migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 107 Latin America migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 108 Latin America migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 109 Latin America migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 110 Latin America migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 111 Brazil migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 112 Brazil migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 113 Brazil migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 114 Brazil migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 115 Brazil migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 116 Argentina migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 117 Argentina migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 118 Argentina migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 119 Argentina migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 120 Argentina migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 121 MEA migraine drugs market, by region, 2018 - 2030 (USD Million)
  • Table 122 MEA migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 123 MEA migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 124 MEA migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 125 MEA migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 126 MEA migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 127 South Africa migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 128 South Africa migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 129 South Africa migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 130 South Africa migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 131 South Africa migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 132 Saudi Arabia migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 133 Saudi Arabia migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 134 Saudi Arabia migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 135 Saudi Arabia migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 136 Saudi Arabia migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 137 UAE migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 138 UAE migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 139 UAE migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 140 UAE migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 141 UAE migraine drugs market, by availability, 2018 - 2030 (USD Million)
  • Table 142 Kuwait migraine drugs market, by treatment, 2018 - 2030 (USD Million)
  • Table 143 Kuwait migraine drugs market, by therapeutic class, 2018 - 2030 (USD Million)
  • Table 144 Kuwait migraine drugs market, by route of administration, 2018 - 2030 (USD Million)
  • Table 145 Kuwait migraine drugs market, by age group, 2018 - 2030 (USD Million)
  • Table 146 Kuwait migraine drugs market, by availability, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Migraine Drugs market: market outlook
  • Fig. 14 Migraine Drugs competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Migraine Drugs market driver impact
  • Fig. 18 Migraine Drugs market restraint impact
  • Fig. 19 Migraine Drugs market: Treatment movement analysis
  • Fig. 20 Migraine Drugs market: Treatment outlook and key takeaways
  • Fig. 21 Acute market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Preventive estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Migraine Drugs market: Therapeutic Class movement analysis
  • Fig. 24 Migraine Drugs market: Therapeutic Class outlook and key takeaways
  • Fig. 25 CGRP monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 CGRP small molecule antagonists market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Acetylcholine inhibitors/ neurotoxins market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Triptans market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Ditans market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Ergot alkaloids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Migraine Drugs market: Route of Administration movement analysis
  • Fig. 34 Migraine Drugs market: Route of Administration outlook and key takeaways
  • Fig. 35 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Migraine Drugs market: Age Group movement analysis
  • Fig. 39 Migraine Drugs market: Age Group outlook and key takeaways
  • Fig. 40 Pediatric market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Adult market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Geriatric market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Migraine Drugs market: Availability movement analysis
  • Fig. 44 Migraine Drugs market: Availability outlook and key takeaways
  • Fig. 45 Prescription Drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Over-the-Counter (OTC) Drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Global Migraine Drugs market: Regional movement analysis
  • Fig. 48 Global Migraine Drugs market: Regional outlook and key takeaways
  • Fig. 49 Global Migraine Drugs market share and leading players
  • Fig. 50 North America, by country
  • Fig. 51 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 U.S. key country dynamics
  • Fig. 53 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Canada key country dynamics
  • Fig. 55 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Mexico key country dynamics
  • Fig. 57 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 UK key country dynamics
  • Fig. 60 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Germany key country dynamics
  • Fig. 62 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 France key country dynamics
  • Fig. 64 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Italy key country dynamics
  • Fig. 66 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Spain key country dynamics
  • Fig. 68 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Denmark key country dynamics
  • Fig. 70 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Sweden key country dynamics
  • Fig. 72 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Norway key country dynamics
  • Fig. 74 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 China key country dynamics
  • Fig. 77 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Japan key country dynamics
  • Fig. 79 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 India key country dynamics
  • Fig. 81 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Thailand key country dynamics
  • Fig. 83 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 South Korea key country dynamics
  • Fig. 85 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Australia key country dynamics
  • Fig. 87 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Brazil key country dynamics
  • Fig. 90 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Argentina key country dynamics
  • Fig. 92 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 94 South Africa key country dynamics
  • Fig. 95 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Saudi Arabia key country dynamics
  • Fig. 97 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 UAE key country dynamics
  • Fig. 99 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Kuwait key country dynamics
  • Fig. 101 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Market share of key market players- Migraine Drugs market